These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 1646776

  • 21. Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.
    den Boer MO, Somers JA, Saxena PR.
    Br J Pharmacol; 1992 Oct; 107(2):577-83. PubMed ID: 1330188
    [Abstract] [Full Text] [Related]

  • 22. Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.
    den Boer MO, Heiligers JP, Saxena PR.
    Br J Pharmacol; 1991 Sep; 104(1):183-9. PubMed ID: 1664762
    [Abstract] [Full Text] [Related]

  • 23. The pharmacology of current anti-migraine drugs.
    Peroutka SJ.
    Headache; 1990 Jan; 30(1 Suppl):5-11; discussion 24-8. PubMed ID: 1969855
    [Abstract] [Full Text] [Related]

  • 24. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors.
    Schoeffter P, Hoyer D.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):135-8. PubMed ID: 2552330
    [Abstract] [Full Text] [Related]

  • 25. Sumatriptan in acute migraine: pharmacology and review of world experience.
    Peroutka SJ.
    Headache; 1990 Jul; 30 Suppl 2():554-60. PubMed ID: 2177047
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
    Buzzi MG, Moskowitz MA.
    Cephalalgia; 1991 Sep; 11(4):165-8. PubMed ID: 1660351
    [Abstract] [Full Text] [Related]

  • 31. Anti-migraine drugs in development: advances in serotonin receptor pharmacology.
    Humphrey PP, Feniuk W, Perren MJ.
    Headache; 1990 Jan; 30(1 Suppl):12-6; discussion 24-8. PubMed ID: 2157682
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
    Chambers MS, Street LJ, Goodacre S, Hobbs SC, Hunt P, Jelley RA, Matassa VG, Reeve AJ, Sternfeld F, Beer MS, Stanton JA, Rathbone D, Watt AP, MacLeod AM.
    J Med Chem; 1999 Feb 25; 42(4):691-705. PubMed ID: 10052976
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites.
    Peroutka SJ, McCarthy BG.
    Eur J Pharmacol; 1989 Apr 12; 163(1):133-6. PubMed ID: 2545459
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.